Posted by Michael Wonder on 09 Dec 2021
Heron Therapeutics announces FDA approval of a significant indication expansion for Zynrelef
9 December 2021 - Approval provides a significantly broader indication for Zynrelef, now covering approximately 7 million procedures a year.
Heron Therapeutics today announced that the U.S. FDA has approved its supplemental new drug application for ynrelef (bupivacaine and meloxicam) extended release solution to significantly expand the indication.
Zynrelef is now indicated in adults for soft tissue or periarticular instillation to produce post-surgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.
